昭衍新药(06127.HK)高管提前终止股份减持计划
昭衍新药(06127.HK)公布,高级管理人员顾静良及其一致行动人徐洁在2021年4月14日披露减持计划前,分别持有公司股份17.36万股、8.54万股,持股比例分别为0.0641%、0.0315%。上述股份来源於首发前限售股份、股权激励股份及公司资本公积金转增股份等其他方式。
顾静良及其一致行动人徐洁於2021年4月14日披露了减持计划,自减持计划公告之日起15个交易日後6个月内,通过上海证券交易所集中竞价的交易方式分别减持不超过4.34万股、8.37万股。
截止公告日,顾静良及其一致行动人徐洁分别减持了4.3万股、8.12万股。因顾静良和徐洁减持股份数量已达其预期减持数量,决定提前终止股份减持计划。(el/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.